Kite Pharma (KITE) Being Defended At Cowen & Co.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Cowen Weighs in on Kite Pharma (KITE) Following One Fatal Cerebral Edema Case
May 8, 2017 12:02 PM EDTCowen analyst Thomas Shrader weighed in on Kite Pharma (NASDAQ: KITE) amid news there was one fatal grade 5 cerebral edema case after treatment with KTE-C19 in ZUMA-1 expansion trial.
Shrader noted that at this point, no clinical hold has been issued on KTE-C19... More
